Vertex Pharmaceuticals, the Cambridge, MA-based developer of telaprevir for hepatitis C, raised $191.3 million from the sale of 7.5 million shares at $25.50 apiece, the company said. Goldman Sachs & Co. is serving as the sole book runner for the offering, and it has an option to buy another 1.1 million shares at the same terms. Vertex said it had $832 million in cash and investments on hand at the end of June, when it last reported quarterly finances.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
